Implementation of an ivermectin-based community treatment strategy for the elimination of onchocerciasis or lymphatic filariasis has been delayed in Central Africa because of the occurrence of serious adverse events, including death, in persons with high levels of circulating Loa loa microfilariae. The LoaScope, a fieldfriendly diagnostic tool to quantify L. loa microfilariae in peripheral blood, enables rapid, point-of-care identification of persons at risk for serious adverse events.
Test-and-Not-Treat Str ategy for Onchocerciasis M ass drug administration with regimens containing ivermectin is the main strategy for the elimination of lymphatic filariasis and onchocerciasis. Although ivermectin is generally safe, the distribution of the drug has been associated with serious adverse events in central African countries. Since 1990, more than 500 cases of characteristic encephalopathy after ivermectin treatment, 1 including approximately 60 fatal cases, have occurred during mass drug administration and have been reported to the Mectizan Donation Program. These neurologic serious adverse events have occurred exclusively in persons with Loa loa microfilarial densities of greater than 30,000 microfilariae (mf) per milliliter of blood 1, 2 and are presumed to be related to eosinophil-mediated inflammation around dying microfilariae, microembolization with subsequent loss of vascular integrity in the central nervous system, or both.
Current World Health Organization guidelines allow the implementation of ivermectin-based mass drug administration in areas where onchocerciasis is mesoendemic or hyperendemic because the potential benefits of mass drug administration are thought to outweigh the risk of serious adverse events associated with ivermectin, although the guidelines stipulate that enhanced surveillance for adverse events is required. 3 However, areas in which loiasis is endemic and onchocerciasis is hypoendemic are spread throughout Central Africa, 4 and these parasitic diseases remain a serious problem. For these areas, a test-and-not-treat strategy has been proposed, in which persons with high L. loa microfilarial loads, who are at risk for serious adverse events, are excluded from ivermectin distribution and the remaining population (typically >95%) can be treated safely.
Successful implementation of the test-and-nottreat strategy requires a rapid, point-of-contact, field-friendly, and highly accurate method to quantify L. loa microfilariae. To this end, the LoaScope, a mobile-telephone-based videomicroscope (previously known as the CellScope Loa), was developed. 5 With the use of a smartphone coupled to a simple optical device, the LoaScope automatically counts L. loa microfilariae in peripheral blood collected in disposable rectangular capillary tubes without the need for sample processing (Fig. S1 in the Supplementary Appendix, available with the full text of this article at NEJM.org). 5 To advance the elimination of Onchocerca volvulus and L. loa in countries in Central Africa in which onchocerciasis and loiasis are coendemic, the feasibility of this test-and-nottreat strategy was tested in the Okola health district in Cameroon, where the distribution of ivermectin was halted in 1999 after the occurrence of encephalopathy related to L. loa infection.
Me thods

Study Site
The Okola health district (Fig. S2 in the Supplementary Appendix) includes 11 administrative health areas where mass drug administration was halted in 1999 by the Ministry of Public Health after 23 cases of encephalopathy occurred during the first treatment campaign. Mass drug administration resumed in 5 of the 11 areas in which onchocerciasis was deemed to be hyperendemic or mesoendemic (prevalence of onchocercal nodules among men, >20%). In 2013, the results of nodule surveys performed in the 6 excluded health areas showed prevalences of 6 to 40%, which is consistent with hypoendemic or mesoendemic onchocerciasis. 6 L. loa infection is highly endemic in the entire Okola health district.
7,8
Study Design
The test-and-not-treat strategy was implemented in 92 villages in the six health areas in which the population has been untreated since 1999. The location of the 92 villages and the timeline of the test-and-not-treat project are shown in Figures T h e ne w e ngl a nd jou r na l o f m e dicine pregnant participants who were excluded from ivermectin distribution because of high L. loa microfilariae counts were administered 400 mg of albendazole for intestinal deworming. Women who reported that they were pregnant did not receive treatment with ivermectin or albendazole but were offered iron and folic acid tablets. Ivermectin and albendazole were donated by Merck and GlaxoSmithKline, respectively, through the national program to eliminate onchocerciasis and lymphatic filariasis in Cameroon. KLA-Tencor provided in-kind donations related to the assembly of the LoaScope devices. Each participant was given a card ( Fig. S4 in the Supplementary Appendix) that listed their L. loa microfilariae count, treatment received, and a contact telephone number for questions and for reporting of adverse events.
This study was authorized by the National Ethics Committee of Cameroon, and the protocol, available at NEJM.org, was approved by the Division of Operational Research at the Ministry of Health. All the authors vouch for the accuracy and completeness of the reported data and analyses and for the fidelity of the study to the protocol.
Quantification of L. loa Microfilariae and Exposure to O. volvulus
The LoaScope and its performance have been described previously. 5 A cutoff L. loa microfilarial density of 26,000 mf per milliliter of blood was selected initially as the threshold below which ivermectin was administered; this threshold was chosen to attain a false positive rate below 1 in 1000 and a false negative rate below 1 in 10 million for the clinical threshold of 30,000 mf per milliliter, 5 below which no neurologic serious adverse events were observed in previous studies. [9] [10] [11] Two weeks after initiation of the study, after 7065 participants had been assessed, a case of conjunctival hemorrhage, as described previously, 12 occurred in a participant who had an L. loa microfilarial density of 24,599 mf per milliliter, as assessed by LoaScope testing. For potential safety reasons, the risk threshold was decreased to 20,000 mf per milliliter for the remainder of the study.
Thick blood smears with a calibrated volume of 50 μl were obtained as a backup for the blood samples that could not be analyzed with a LoaScope; the blood smears were used to identify and quantify Mansonella perstans microfilariae and to corroborate the accuracy of the LoaScope. The blood smears were examined by two microscopists who were unaware of the LoaScope results. Dried blood spots were collected on filter paper and archived at a storage temperature of −80°C. To assess exposure to O. volvulus, the SD Bioline Onchocerciasis IgG4 Rapid Test (Standard Diagnostics) was used to determine the presence of anti-Ov16 IgG4 antibodies in 10-μl eluates derived from each blood spot. 13, 14 The results were examined and recorded 24 hours after the eluates were dropped into the test sample well.
Monitoring of Posttreatment Adverse Reactions
Adverse events were monitored by two surveillance teams, each of which included a physician and a driver, with the assistance of selected community members and local nurses. The surveillance teams visited each village on days 1, 2, 3, and 6 after treatment, examined all participants who reported adverse events, and provided treatment for symptoms when clinically indicated. In addition, the teams toured the entire community by car to identify additional participants with posttreatment symptoms. All participants with a potential posttreatment adverse event underwent systematic evaluation, which was performed with the use of a standardized form (Fig. S5 in the Supplementary Appendix). A Karnofsky performance status score was assigned to each patient at the time of examination (scores range from 0 to 100, with higher scores indicating better functional status). A global adverse-event severity grade was assigned retrospectively to each person who presented with an adverse event; grade 1 indicated mild symptoms not requiring intervention; grade 2, moderate symptoms with local or noninvasive intervention indicated; grade 3, severe symptoms limiting self-care activities of daily living; grade 4, severe symptoms requiring hospitalization; and grade 5, death. Clinical management was based on reference guidelines.
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Statistical Analysis
Medians and interquartile ranges were used to indicate the central tendency and dispersion of the data. Multivariable logistic regression was used to examine associations between individual factors (sex, age, L. Loa microfilarial density [as assessed by LoaScope testing], presence of anti-
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Ov16 IgG4 antibodies, and presence of M. perstans microfilariae [as assessed by thick blood smear microscopy]) and the occurrence of adverse events. The logistic-regression coefficients were used to calculate population-attributable fractions. 16 Thick blood smear microscopy was used as the reference standard in the assessment of the specificity and negative predictive value of LoaScope testing.
R esult s
Population Characteristics
A total of 16,259 participants were examined during the test-and-not-treat process (Fig. 1) . The median age of the examined populations in the various health areas ranged from 17 to 26 years. The sex distribution was relatively equal (48% male). The prevalence of onchocerciasis in the six health areas varied from 15.3 to 29.9%. The prevalence of L. loa microfilaremia varied from 15.3 to 22.8%, and the percentage of participants with an L. loa microfilarial density greater than 20,000 mf per milliliter of blood, as assessed by LoaScope testing, ranged from 1.3% in the Ngoya health area to 2.4% in the Nlong and Ekekam III health areas (Table 1, and Table S2 in the Supplementary Appendix).
Test-and-Not-Treat Process
The number of participants examined per village per day was typically between 50 and 100. The mean time from finger prick to the LoaScope result was 2 to 3 minutes. The LoaScope results were immediately available for 16,099 of 16,259 participants (99.0%) and were delayed for 160 participants (1.0%) because of technical problems that led to the use of thick blood smear microscopy to determine the microfilarial density. Ivermectin was administered in 15,522 participants (95.5%), all of whom had an L. loa microfilarial density below the risk threshold.
A total of 737 participants (4.5%) were excluded from ivermectin distribution: 340 (2.1%) T h e ne w e ngl a nd jou r na l o f m e dicine were excluded because the L. loa microfilarial density was above the risk threshold, 228 (1.4%) were excluded because of poor health (signs or symptoms consistent with a serious acute or chronic concomitant illness) or inebriation, and 169 (1.0%) were excluded because they were pregnant or breast-feeding. The percentage of excluded participants per village varied from 0 to 15.1% (Fig. S6 in the Supplementary Appendix).
All excluded participants (except pregnant women) received 400 mg of albendazole. The median treatment coverage in the six health areas was 55% of the total population (interquartile range among villages, 42.9 to 64.1) and 64% of the target population. The prevalence of onchocerciasis was 22.0% among the participants who received ivermectin, 25.4% among the women who were excluded because of pregnancy or illness, and 33.5% among the participants with an L. loa microfilarial density above the risk threshold. Thus, participants potentially infected with O. volvulus who did not receive treatment with ivermectin because of L. loa microfilaremia represented 0.7% of the examined population.
Frequency and Types of Adverse Events
Among the 15,522 participants who received ivermectin, 934 (6.0%) presented for evaluation of posttreatment adverse events. The incidence of adverse events decreased slightly from 6.6% (464 of 7065 participants) to 5.6% (470 of 8457 participants) (P<0.001) after the risk threshold was lowered from 26,000 to 20,000 mf per milliliter of blood. A total of 2818 adverse events were recorded; dermatologic manifestations were the most common adverse events, followed by systemic and rheumatologic manifestations (Table 2). A total of 869 participants (93.0%) had a Karnofsky performance status score of 90, and 65 (7.0%) had a score of 80. Among the participants who presented with posttreatment adverse events, a global adverse-event severity grade of 1 was assigned to 88 (9.4%), a grade of 2 was assigned to 843 (90.3%), and a grade of 3 was assigned to 3 (0.3%). The 3 participants with grade 3 adverse events were female; were 6, 63, and 70 years old; and were bedridden during the first visit by the medical team owing to headache, myalgias and arthralgias, and abdominal pain, respectively. Two participants had no laboratory evidence of onchocerciasis or loiasis, and 1 had a positive IgG4 test result for the Ov16 antigen and had an L. loa microfilarial density of 21,560 mf per milliliter. No hospitalizations (grade 4 adverse events) or deaths (grade 5 adverse event) were reported. All adverse events resolved within 1 week after onset without further treatment or with basic supportive therapy (antihistamines, nonsteroidal antiinflammatory drugs, or acetaminophen).
Both L. loa microfilaremia and the presence Table 2 . Adverse Events Recorded during the 6-Day Posttreatment Surveillance Process.
T h e ne w e ngl a nd jou r na l o f m e dicine microscopic examination of thick blood smears Fig. 3 ). The specificity of LoaScope testing to provide a measurement of an L. loa microfilarial density below 20,000 mf per milliliter of blood in a person for whom thick blood smear microscopy indicated an L. loa microfilarial density below 20,000 mf per milliliter of blood was 99.7% (95% confidence interval [CI], 99.6 to 99.8), and the negative predictive value was 99.7% (95% CI, 99.6 to 99.7).
Discussion
The extension of ivermectin-based mass drug administration to areas in which onchocerciasis is hypoendemic and loiasis is coendemic remains a large obstacle to the success of onchocerciasis elimination programs in Africa. In the current study, a LoaScope-based test-and-not-treat strategy was used to safely treat more than 15,000 persons with ivermectin in such an area. Despite an initial reticence among the people in some villages to participate on account of the memory of serious adverse events (including deaths) that occurred in 1999, a total of 16,259 of the 22,842 persons 5 years of age or older recorded during the initial census (71.2%) participated in the testand-not-treat campaign. This rate of participation suggests that test-and-not-treat is an acceptable strategy even in populations with a history of ivermectin-related serious adverse events. We believe that fear of serious adverse events, although not formally assessed, was probably the main reason for nonparticipation. During the first mass drug administration campaign in the Okola health district in 1999, a total of 23 cases of neurologic serious adverse events, including 3 deaths, were recorded among the 6000 persons who received ivermectin before mass drug administration was stopped. 17 The incidence of neurologic serious adverse events that occurred within 1 week after treatment with ivermectin was 38 per 10,000 persons, and the incidence of death resulting from adverse events that started within 1 week after treatment with ivermectin was 5 per 10,000 persons. Extrapolation of these data to the population enrolled in the current study shows that approximately 62 cases of neurologic serious adverse events and 8 deaths would have been anticipated. Although 6.0% of the participants reported ivermectin-associated adverse events during the test-and-not-treat campaign, the percentage was lower than that typically observed after ivermectin-based mass drug administration for onchocerciasis in areas in which loiasis is not endemic (13.1% among persons in southeast Nigeria 18 ; 12% and 20% in northern Cameroon in areas where onchocerciasis is mesoendemic and hyperendemic, respectively 19 ; and 21.4% in eastern Sudan) 20 and much lower than the 26.3% recorded in a neighboring area of central Cameroon where L. loa infection is endemic. 2 The most likely explanation for this finding is that onchocerciasis is hypoendemic to mesoendemic in Okola.
LoaScope operators underwent a 1-hour training session 2 weeks before the field operations. This training sufficed for the entire study, and the teams noted the ease of use and reliability of the device despite daily use and demanding field conditions. Because L. loa microfilariae show a daytime periodicity, 21 LoaScope examinations (and treatment) started at 10 a.m. and ended at Multivariable logistic regression was used to examine associations between individual factors and the occurrence of adverse events. The dotted line (odds ratio of 1) represents an absence of association. Constant (odds ratio of 0.017) represents the odds ratio of adverse events when all covariates are set to zero. L. loa microfilarial density was measured as the number of L. loa microfilariae (mf) per milliliter of blood. Ov16 IgG4+ denotes a positive test result for IgG4 antibodies against the Ov16 antigen, and Ov16 IgG4− a negative test result for IgG4 antibodies against the Ov16 antigen. I bars indicate 95% confidence intervals. is impractical at the community level, this regimen could be used in this context. The identification of persons who were excluded from ivermectin distribution in the current study and the provision of doxycycline treatment for those persons are ongoing. In summary, this test-and-not-treat strategy based on a scalable point-of-contact tool that allows for the rapid identification (and exclusion from ivermectin-based treatment) of persons at risk for serious adverse events related to L. loa infection has enabled district-level community treatment of onchocerciasis. Although this testand-not-treat strategy was motivated by the need to tackle the problem of hypoendemic onchocerciasis in Central Africa, it could also be considered for other areas in which onchocerciasis and loiasis are coendemic. Many, but not all, areas in which onchocerciasis is mesoendemic or hyperendemic are already covered by community-directed treatment with ivermectin; a testand-not-treat strategy would target persons who have not previously received ivermectin and persons who are routinely nonadherent to treatments. Cutoff 1 (8000 mf per milliliter of blood) was used for information relevant to an increased likelihood of adverse events provided to each participant; all persons with an L. loa microfilarial density between cutoff 1 and cutoff 3 during the first 2 weeks of the study and at cutoff 2 after the first 2 weeks were told -before ivermectin treatment was proposed -that they might have a mild adverse event. For persons with an L. loa microfilarial density below cutoff 1, ivermectin treatment was just proposed, with no other specific message. Cutoff 2 and cutoff 3 were the risk thresholds that were used to exclude persons from ivermectin distribution. Two weeks after initiation of the study, the initial risk threshold of 26,000 mf per milliliter (cutoff 3) was lowered to 20,000 mf per milliliter (cutoff 2) after a case of conjunctival hemorrhage occurred in a participant who had an L. loa microfilarial density of 24,599 mf per milliliter, as assessed by LoaScope testing. The right tails of the distribution of L. loa microfilarial density were censored for counts above 50,000 mf per milliliter. Explore a new page designed specifically for practicing clinicians, the NEJM Clinical Practice Center, at nejm.org/clinical-practice-center. Find practice-changing research, reviews from our Clinical Practice series, a curated collection of clinical cases, and interactive features designed to hone your diagnostic skills.
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